Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness

AIDS

Volumn 24, Issue 14, 2010, Pages 2201-2209

  Delaney, Joseph A C ^a   Scherzer, Rebecca ^b,c   Biggs, Mary L ^d   Shliplak, Michael G ^b,c   Polak, Joseph F ^e   Currier, Judith S ^f   Kronmal, Richard A ^d   Wanke, Christine ^e   Bacchetti, Peter ^b   O'Leary, Daniel ^e   Tien, Phyllis C ^b,c   Grunfeld, Carl ^b,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atherosclerosis; carotid intima media thickness; HIV; tenofovir

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ADENINE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RISK FACTORS; TUNICA INTIMA; TUNICA MEDIA;

EID: 77956229537     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833d2132     Document Type: Article

References (40)

1. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroCon-version to AIDS and Death in Europe. Lancet 2000; 355:1158-1159.
2. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
3. Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, et al., Working Group 1. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008; 118:e20-e28.
4. Folsom AR, Kronmal RA, Detrano RC, O'Leary DH, Bild DE, Bluemke DA, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2008; 168:1333-1339.
5. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14-22.
6. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al., for the study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841-1849.
7. Sankatsing RR, Wit FW, Vogel M, de Groot E, Brinkman K, Rockstroh JK, et al. Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to nonnucleoside reverse transcriptase inhibitors. Atherosclerosis 2009; 202:589-595.
8. Lekakis J, Tsiodras S, Ikonomidis I, Palios J, Poulakou G, Rallidis L, et al. HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clin Sci (Lond) 2008; 115:189-196.
9. MaggiP,SerioG,EpifaniG,FiorentinoG,SaracinoA,FicoC,etal. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14:F123-F128.
10. Maggi P, Lillo A, Perilli F, Maserati R, Chirianni A, PREVALEAT Group. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 2004; 18:1023-1028.
11. Seminari E, Pan A, Voltini G, Carnevale G, Maserati R, Minoli L, et al. Assessment of atherosclerosis using carotid ultrasono-graphy in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002; 162:433-438.
12. Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, et al., AACTG 5078 Study Team. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19:927-933.
13. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, et al., Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 2001; 15:329-334.
14. Johnsen S, Dolan SE, Fitch KV, Kanter JR, Hemphill LC, Connelly JM, et al. Carotid intimal-medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab 2006; 91:4916-4924.
15. Mercié P, Thiébaut R, Aurillac-Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Cipriano C, et al., Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med 2005; 6:380-387.
16. Mangili A, Gerrior J, Tang AM, O'Leary DH, Polak JK, Schaefer EJ, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis 2006; 43:1482-1489.
17. Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, et al. Low CD4R T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22:1615-1624.
18. Eckhardt BJ, Glesby MJ. Antiretroviral therapy and cardiovascular risk: are some medications cardioprotective? Curr Opin HIV AIDS 2008; 3:226-233.
19. Leone S, Amitrano M, D'Avanzo A, Acone N, Giglio S. Carotid artery intima-media thickness in highly treated HIV-1 patients. Infez Med 2008; 16:15-20.
20. Thiébaut R, Aurillac-Lavignolle V, Bonnet F, Ibrahim N, Cipriano C, Neau D, et al., Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999-2004. AIDS 2005; 19:729-731.
21. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008; 196:720-726.
22. Raftery AE. Bayesian model selection in social research (with Discussion). Sociol Methodol 1995; 25:111-196.
23. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006; 163:860-869.
24. Li R, Duncan BB, Metcalf PA, Crouse JR 3rd, Sharrett AR, Tyroler HA, et al. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 1994; 25:2377-2383.
25. Riley WA, Barnes RW, Bond MG, EvansG, Chambless LE, Heiss G. High resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities (ARIC) Study. J Neuroi-mag 1991; 1:168-172.
26. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, et al., Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference. Mannheim intima-media thickness consensus. Cerebrovasc Dis 2004; 18:346-349.
27. Raftery AE, Madigan D, Hoeting JA. Bayesian model averaging for regression models. J Am Stat Assoc 1997; 92:179-191.
28. Volinsky CT, Madigan D, Raftery AE, Kronmal RA. Bayesian model averaging in proportional hazard models: assessing stroke risk. J R Stat Soc C 1997; 46:433-448.
29. Viallefont V, Raftery AE, Richardson S. Variable selection and Bayesian model averaging in epidemiological case-control studies. Stat Med 2001; 20:3215-3230.
30. Hoeting JA, Madigan D, Raftery AE, Volinsky CT. Bayesian model averaging: a tutorial (with Discussion). Stat Sci 1999; 14:382-401.
31. Rubin DB. Multiple imputation after 18R years. J Am Stat Assoc 1996; 91:473-489.
32. Tungsiripat M, Kitch D, Glesby M, Gupta S, Mellors J, Moran L, Jones L, Alston-Smith B, Rooney J, Aberg J. A pilot study to determine the effect on dyslipidemia of the addition of teno-fovir to stable background ART in HIV-infected subjects: results from the A5206 study team. http://www.natap.org/ 2009/CROI/croi-80.htm. [Accessed 9 July 2009]
33. Llibre JM, Domingo P, Palacios R, Santos J, Pérez-Elías MJ, Sánchez-de la Rosa R, et al., Lipo-Rec Study Group. Lipo-Rec Study Group. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2006; 20:1407-1414.
34. Valantin MA, Bittar R, de Truchis P, Bollens D, Slama L, Giral P, et al., TOTEM Trial Group. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fuma-rate R emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother 2010; 65:556-561.
35. Girard PM, Cabié A, Michelet C, Verdon R, Katlama C, Mercié P, et al., COOL Study Team. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.J Antimicrob Chemother 2009; 64:126-134.
36. DeChristoforo R, Penzak SR. Tenofovir: a nucleotide analogue reverse-transcriptase inhibitor for treatment of HIV infection. Am J Health Syst Pharm 2004; 61:86-98.
37. Greenland S. Bayesian perspectives for epidemiological research. II: Regression analysis. Int J Epidemiol 2007; 36:195-202.
38. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
39. Madden E, Lee G, Kotler DP, Wanke C, Lewis CE, Tracy R, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22:707-715.
40. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.